CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
Reports
The burden of acute coronary syndrome: The second leading cause of death in Canada
November 1, 2010
Key contacts
Upcoming events
Swiss Biotech Day 2026
CRA is a proud sponsor of the premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful...
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...